JSPR files 8-K, to unveil briquilimab CSU trial update July 7 webcast

Jasper Therapeutics, Inc. (Nasdaq: JSPR) filed a Form 8-K dated July 7, 2025 to disclose a material corporate event under Item 8.01.

Rhea-AI Filing Summary

Jasper Therapeutics, Inc. (Nasdaq: JSPR) filed a Form 8-K dated July 7, 2025 to disclose a material corporate event under Item 8.01.

The company issued a press release (Exhibit 99.1) announcing updated data from its BEACON Phase 1b/2a study evaluating subcutaneous briquilimab in adults with chronic spontaneous urticaria. Jasper will host a conference call and webinar on July 7, 2025 at 8:30 a.m. EDT to discuss the new findings and provide a program update. A supporting investor presentation is furnished as Exhibit 99.2. No financial statements or earnings figures accompany this filing.

Key administrative details include the trading symbols JSPR (common stock) and JSPRW (warrants), and confirmation of listing on The Nasdaq Stock Market LLC. The filing contains customary signatures and an iXBRL cover page file (Exhibit 104).

Positive

• Pipeline visibility: Company furnishes updated clinical data and schedules investor call, signaling progress in its briquilimab program.

Negative

• None.

Insights

Biotech Equity Analyst

TL;DR – Neutral disclosure; investors await detailed efficacy and safety numbers.

The 8-K merely announces that Jasper will present updated briquilimab CSU data. Without the underlying metrics—response rates, durability, safety profile—capital-market impact is indeterminate. Nonetheless, the filing confirms program momentum and management’s commitment to transparent communication via a same-day webcast. Investors will focus on whether briquilimab can demonstrate clinically meaningful anti-mast-cell activity relative to standard of care and rival anti-IgE/anti-IgG therapies. Absent quantitative results, I assign a neutral rating pending the actual data drop.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jasper Therapeutics (JSPR) announce in its July 7, 2025 Form 8-K?

The company reported updated Phase 1b/2a data for subcutaneous briquilimab in chronic spontaneous urticaria and scheduled a same-day webcast.

Which exhibits accompany the JSPR 8-K filing?

Exhibit 99.1 is the press release, Exhibit 99.2 is the investor presentation, and Exhibit 104 is the iXBRL cover page.

When will the Jasper Therapeutics conference call take place?

The webcast is set for July 7, 2025 at 8:30 a.m. Eastern Daylight Time.

Does the 8-K include any financial results or earnings data?

No, the filing is limited to a clinical program update and contains no financial statements or earnings figures.

What exchange and symbols does Jasper Therapeutics trade under?

Common stock trades on Nasdaq as JSPR; redeemable warrants trade as JSPRW.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2025 - 07:35 AM Learn about SEC filing dates

false 0001788028 0001788028 2025-07-07 2025-07-07 0001788028 JSPR:VotingCommonStockParValue0.0001PerShareMember 2025-07-07 2025-07-07 0001788028 JSPR:RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member 2025-07-07 2025-07-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 7, 2025

JASPER THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-39138		84-2984849
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2200 Bridge Pkwy Suite #102
Redwood City, California 94065

(Address of Principal Executive Offices) (Zip Code)

(650) 549-1400

Registrant’s telephone number, including area code

N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)		(Trading Symbol)		(Name of exchange on which registered)
Voting Common Stock, par value $0.0001 per share		JSPR		The Nasdaq Stock Market LLC
Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00		JSPRW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On July 7, 2025, Jasper Therapeutics, Inc. (the “Company”) issued a press release reporting updated data from the Company’s BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic spontaneous urticaria and providing an update on the program and disclosing that the Company will hold a conference call and webinar at 8:30 am Eastern Daylight Time on July 7, 2025 to present the updated data from the BEACON Phase 1b/2a study and to provide an update on the program.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the presentation to be used in connection with the conference call and webinar on July 7, 2025 is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Number		Description
99.1		Press Release, dated July 7 2025.
99.2		Presentation—Jasper Therapeutics: Corporate Presentation July 2025.
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

1 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	JASPER THERAPEUTICS, INC.
Date: July 7, 2025	By:	/s/ Herb Cross
		Name:	Herb Cross
		Title:	Chief Financial Officer

2